The relation of parafibromin expression with clinicopathological factors in invasive breast carcinomas

Abstract

Objective: We aimed to find the relationship between parafibromin expression and clinicopathologic variables of breast carcinoma. Material and Method:Ninety-seven cases of invasive breast carcinoma diagnosed at our department between the years 2010-2013 were included in the study. The parafibromin expression state was compared with the estrogen receptor, progesterone receptor, cerbB2, Ki67 results, and the clinicopathological variables.Results: Among 97 breast carcinoma cases, 66 (68%) were invasive ductal carcinoma. The average age was 54.3 (min:25, max:100), and the average tumor size was 31.1 mm (min:7, max:120). Lymph node metastasis was detected in 58% of the cases. Eleven were diagnosed with metastasis amongst 77 cases whose distant metastasis data could be reached. Eleven cases were lost due to breast carcinoma. As the tumor grade increased, the possibility of distant metastasis and lymph node metastasis increased as well (p=0.04, p=0.05, respectively). The mean follow-up duration of the cases was 26.6±9.8 (min. 6, max. 53) months, and there was no significant difference in survival between the other variables. Of the cases, 21.6% were negative, 9.3% were (+) positive, 11.3% were (++) positive and 57.7% were (+++) positive for parafibromin. It was found that there was an inverse correlation between the Ki67 proliferation index and lymph node metastasis and the parafibromin expression (p=0.018, p=0.029, respectively). Conclusion:We suggest that parafibromin may be a possible prognostic and predictive parameter for breast carcinomas. As the data on this matter in the literature is limited, it would be beneficial to investigate the matter and evaluate its relationship with survival in larger series.

UBR5 targets tumor suppressor CDC73 proteolytically to promote aggressive breast cancer

“…Thus, CDC73 may influence T cell-mediated immune responses by regulating the expression of such immune checkpoint molecules and costimulatory molecules. In addition, low expression of CDC73 has also been found associated with adverse pathological parameters in human breast cancer cases [42,43]. Moreover, although the mRNA level of CDC73 in patients is statistically lower in TNBC than non-TNBC, there is an overlapping between them, and the regulation of UBR5 to CDC73 was also observed in non-TNBC cell line MCF-7, indicating that the function of CDC73 and UBR5 may be more wide spread in breast cancers, not limited to TNBC.…”

Prognostic role of parafibromin staining and CDC73 mutation in patients with parathyroid carcinoma: A systematic review and meta‐analysis based on individual patient data

“…Parafibromin is a component of the polymerase associated factor (Paf1) complex that regulates gene transcription and cell growth via histone ubiquitination and methylation, chromatin remodelling and the cyclin D1 and Wnt signalling pathways . The tumour suppressor functions of parafibromin, such as inducing apoptosis and inhibiting the cell cycle, have been illustrated in malignant tumours of many other organs, including colorectal, urogenital, ovarian and breast carcinomas . Theoretically, loss of parafibromin expression could affect one or several tumour‐suppressive mechanisms and propagate an inferior outcome.…”

“…30 The tumour suppressor functions of parafibromin, such as inducing apoptosis and inhibiting the cell cycle, have been illustrated in malignant tumours of many other organs, including colorectal, urogenital, ovarian and breast carcinomas. [31][32][33][34] Theoretically, loss of parafibromin expression could affect one or several tumour-suppressive mechanisms and propagate an inferior outcome. The results of CDC73 sequencing indicated that mutation in this gene was not statistically correlated with recurrence/metastasis or mortality in the current study.…”

The clinicopathological and prognostic significances of CDC73 expression in cancers: a bioinformatics analysis

“…Previously, we investigated the clinicopathological and prognostic significances of parafibromin expression in gastric, colorectal, ovarian, lung, head and neck cancers, and found its down-regulated expression and its inverse link with aggressive behaviors and unfavorable prognosis [ 13 – 18 ]. Parafibromin expression was found to negatively correlate with tumor size, pathological stage, lymphovascular invasion and C-erbB2 expression of breast cancer [ 19 , 20 ]. There was an inverse correlation between lymph node metastasis or depth of invasion and parafibromin expression in urothelial carcinoma [ 21 ].…”